The white paper illustrates how recent lupus launches, including Lupkynis (Aurinia), Benlysta (GSK), and Saphnelo (AstraZeneca), showcase the critical role
Ultomiris (AZ/Alexion) and Empaveli (Appellis) identified as driving greater PNH treatment flexibility and individualized care Exton, Pa., September 26, 2025 –
Spherix Global Insights finds majority of specialists expect Rinvoq’s uptake to accelerate, with potential implications branching to the polymyalgia rheumatica
As patients struggle with treatment burdens and suboptimal outcomes, new pipeline therapies spark hope for meaningful transformation across nAMD, DME,
US Gastroenterologists and hepatologists highlight strong interest in Wegovy for addressing the metabolic roots of MASH. Exton, PA, August 28,
New patient chart audit uncovers rising wave of patient-driven treatment switches in ulcerative colitis and Crohn’s disease, opening the door
TNF biosimilars continue to expand, underscoring the tension between payer-driven cost pressures and pipeline-driven opportunity. EXTON, PA, August 25, 2025
Breakthrough therapies targeting APOL1 and reducing steroid dependence could redefine treatment standards for FSGS EXTON, PA, August 21, 2025 —The
EXTON, PA, August 19, 2025 – Spherix Global Insights announces the upcoming release of its latest Special Topix™ service, Payer
New research from Spherix Global Insights reveal Vertex/CRISPR Therapeutics’ Casgevy holding a competitive edge over bluebird bio’s Zynteglo as preferred
Inclusion body myositis and ASyS identified as most underserved IIM subtypes amid widespread calls for faster, safer, steroid-sparing therapies. EXTON,
Strong efficacy and safety perceptions, as well as favorable administration fuel utilization of the IL-23 class in Crohn’s disease, according
